There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 6, Pfizer Inc's Director, Ronald E. Blaylock, invested $501,085.00 into 13,000 shares of PFE, for a cost per share of $38.55. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money. In trading on Friday, bargain hunters could buy shares of Pfizer Inc (Symbol: PFE) and achieve a cost basis 3.0% cheaper than Blaylock, with shares changing hands as low as $37.40 per share. Pfizer Inc shares are currently trading down about 1% on the day. The chart below shows the one year performance of PFE shares, versus its 200 day moving average:
Looking at the chart above, PFE's low point in its 52 week range is $27.88 per share, with $40.97 as the 52 week high point — that compares with a last trade of $37.49. By comparison, below is a table showing the prices at which PFE insider buying was recorded over the last six months:
| Purchased | Insider | Title | Shares | Price/Share | Value |
|---|---|---|---|---|---|
| 08/06/2020 | Ronald E. Blaylock | Director | 13,000 | $38.55 | $501,085.00 |
The current annualized dividend paid by Pfizer Inc is $1.52/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/30/2020. Below is a long-term dividend history chart for PFE, which can be of good help in judging whether the most recent dividend with approx. 4.0% annualized yield is likely to continue.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
